DOC
Healthpeak Properties, Inc.Evidence as of 2026-09-26The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on DOC
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · Healthpeak Properties, Inc.
Physicians Realty Trust is a self-managed health care real estate company organized to acquire, selectively develop, own, and manage health care properties that are leased to physicians, hospitals and health care delivery systems. The Company invests in real estate that is integral to providing high quality health care. The Company conducts its business through an UPREIT structure in which its properties are owned by…
Management team
- Mr. Antonio Acevedo · Senior Vice President of Asset Management - Outpatient MedicalFind on LinkedIn
- Mr. James A. Croy · Senior Vice President of Leasing - Outpatient MedicalFind on LinkedIn
- Ms. Tracy A. Porter · Executive VP, General Counsel & ESGFind on LinkedIn
- Mr. Scott R. Bohn · Chief Development Officer & Head of LabFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.5 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The desk’s surviving claims present a cautious reading (evidence balance: Cautious, -0.5) supported by high confidence. Reported quarterly revenues rose modestly across the twelve-quarter sample, for example Q1 2022 (fiscal quarter ended 2022-04-27) revenues were $ 130,390,000 and Q3 2023 (fiscal quarter ended 2023-10-27) were $ 138,547,000. Weighted-average diluted shares outstanding climbed from 239,898,462 in Q3 2022 (fiscal quarter ended 2022-10-26) to 249,445,312 in Q3 2023, an increase of roughly 10.1 million diluted shares.
Balance-sheet and valuation evidence adds nuance: long-term debt declined through calendar 2022 then rose in 2023 (from $ 1,818,117,000 as of 2022-12-31 to $ 1,973,037,000 as of 2023-12-31), cash moved from single-digit millions in early 2022 to $ 245,660,000 as of 2023-06-30 then down to $ 156,779,000 as of 2023-12-31, trailing EPS diluted compressed from $ 0.28 in Q3 2022 to $ 0.05 in Q3 2023, the reported trailing P/E is 84.62 (price $ 20.31 / EPS TTM $ 0.24), market cap is $ 14,004,298,651 and enterprise value is $ 22,409,657,651 implying meaningful net leverage (net debt roughly $ 8,405,359,000 as of 2026-06-30).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Reported quarterly revenues rose modestly across the twelve-quarter sample: fiscal Q1 2022 (2022-01-01 to 2022-03-31) revenues $130,390,000; fiscal Q2 2022 (2022-04-01 to 2022-06-30) $132,167,000; fiscal Q3 2022 (2022-07-01 to 2022-09-30) $131,513,000; fiscal Q1 2023 (2023-01-01 to 2023-03-31) $134,344,000; fiscal Q2 2023 (2023-04-01 to 2023-06-30) $135,100,000; fiscal Q3 2023 (2023-07-01 to 2023-09-30) $138,547,000.
XBRL companyfacts · 0001574540-22-000106Weighted-average diluted shares outstanding increased over the sample: Q1 2022 weighted-average diluted shares 238,340,243; Q2 2022 239,006,973; Q3 2022 239,898,462; Q1 2023 248,756,672; Q2 2023 249,228,221; Q3 2023 249,445,312 — indicating a rise of roughly 10.1 million diluted shares between Q3 2022 and Q3 2023.
XBRL companyfacts · 0001574540-22-000106Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The 10-K filed 22 February 2024 added multiple merger-related risks, including litigation risk related to the Merger Agreement, the possibility that completion conditions may not be satisfied, diversion of management time to integration planning, and that pendency of the Mergers could disrupt business relationships and operations.
10-K filed 2024-02-22The 10-K filed 22 February 2024 states that the Exchange Ratio is fixed at 0.674 shares of Healthpeak common stock per Trust common share and will not be adjusted for changes in either party's stock price.
10-K filed 2024-02-22Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
13F filers reported a combined institutional position value of "$13.89B" in DOC for the quarter ended 2026-06-30.
13F holdings · 764 filers · as of 2026-06-30The largest reported institutional holders in that 13F were BlackRock, Inc. at "$1.52B", VANGUARD PORTFOLIO MANAGEMENT LLC at "$1.25B", VANGUARD CAPITAL MANAGEMENT LLC at "$963.3M", STATE STREET CORP at "$941.8M", and JPMORGAN CHASE & CO at "$661.0M".
13F holdings · 764 filers · as of 2026-06-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Several outlets report that Healthpeak raised its full-year 2026 guidance after second-quarter results, citing improved EPS and diluted FFO ranges.
News · finance.yahoo.com · 2026-09-18The same guidance/earnings-driven story was carried by at least one other distinct outlet with similar framing, showing syndicated or repeated coverage of the company-specific update.
News · insidermonkey.com · 2026-09-18Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The reported trailing P/E is 84.62 based on the price of 20.31 and EPS TTM of 0.24.
Valuation inputs · SEC XBRL + stored EOD closeMarket capitalization is 14,004,298,651 and enterprise value is 22,409,657,651, implying meaningful net leverage at the enterprise level.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-specific items in the evidence support a favorable read: revenues showed modest sequential growth across the twelve-quarter sample, cash balances recovered materially by mid-2023, institutional ownership and reported position values are large and growing, and recent headlines report Healthpeak raised 2026 guidance after Q2 — all of which together indicate operational momentum and meaningful market interest. While valuation and leverage metrics are flagged as concerns in the dataset, the operating-cash yield (OCF/market cap ~6.2%) and the concentration of large, reputable institutional holders provide countervailing context about cash generation and investor conviction. In rebuttal to bear points about EPS compression and merger-related risks, the revenue and cash-improvement signals are company-specific facts in the evidence set, and news of raised guidance is reported across multiple outlets; historically, these kinds of operational recoveries and visible institutional accumulation have supported more constructive interpretations of a security’s near-term fundamentals. Evidence strength: revenue and ownership items are strong (direct reported figures and 13F filings), cash and guidance items are moderate-strong (periodic filings and multiple news outlets), and valuation/leverage flags are strong in magnitude but require additional EBITDA/FCF detail for full context.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.33
27 surviving claims rest on 13 distinct sources; the heaviest analyst carries 22% of them, and 100% of what the desk raised survived the debate.
The evidence base is moderately fragile: 27 surviving claims rest on a relatively small set of 13 sources, so single-source updates could shift multiple claims. One analyst accounts for a sizeable share of surviving claims (22%), which raises sensitivity to that contributor's inputs, while the desk’s 100% survival through debate indicates thorough internal vetting rather than independence from concentrated inputs.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
19 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.2 to the score
4 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.8 to the score
2 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.8 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on DOC Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.